Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
5-azacytidine
Ribonucleotide reductase (RNR)
methylation
myelodysplastic syndrome
response to treatment
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
pubmed:
6
11
2021
medline:
15
4
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Ribonucleotide Reductase (RNR) is a two-subunit (RRM1, RRM2) enzyme, responsible for the conversion of ribonucleotides to deoxyribonucleotides required for DNA replication. To evaluate RNR as a biomarker of response to 5-azacytidine, we measured RNR mRNA levels by a quantitative real-time PCR in bone marrow samples of 98 patients with myelodysplastic syndrome (MDS) treated with 5-azacytidine with parallel quantification of the gene promoter's methylation. Patients with low RRM1 levels had a high RRM1 methylation status (
Identifiants
pubmed: 34738857
doi: 10.1080/10428194.2021.1998484
doi:
Substances chimiques
RNA, Messenger
0
Ribonucleotide Reductases
EC 1.17.4.-
Ribonucleoside Diphosphate Reductase
EC 1.17.4.1
Azacitidine
M801H13NRU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM